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OBJECTIVEdTo assess the prevalence of distal sensorimotor polyneuropathy (DSPN) in an
older population and to examine its relationship with prediabetes.
RESEARCH DESIGN AND METHODSdGlucose tolerance status was determined in
61- to 82-year-old participants (n = 1,100) of the population-based Cooperative Health Research
in the Region of Augsburg (KORA) F4 Survey (2006–2008). Clinical DSPN was defined as
bilaterally impaired foot-vibration perception and/or foot-pressure sensation.
RESULTSdPrevalence of clinical DSPN was similar in subjects with known diabetes (22.0%)
and subjects with combined impaired fasting glucose (IFG) and impaired glucose tolerance (IGT)
(23.9%). Among prediabetic subgroups, IFG-IGT, but not isolated-IFG and -IGT, was associated
with a higher risk of clinical DSPN, compared with normal glucose tolerance. A J-shaped asso-
ciation was observed between clinical DSPN and quartiles of 2-h postchallenge glucose, but not
with fasting glucose and HbA1c levels.
CONCLUSIONSdSubjects with IFG-IGT and known diabetes had a similar prevalence of
clinical DSPN. Elevated 2-h postload glucose levels appeared important for disease risk.
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D istal sensorimotor polyneuropathy(DSPN) is an important complicationof type 2 diabetes. It is still unclear
whether nerve disorders are already man-
ifest in subjects with prediabetes (1).
The aim of the current study was to
evaluate the prevalence of DSPN in a rep-
resentative sample of the older population
and to study the association between
prediabetes and DSPN. In addition, we
examined the relationship between glu-
cose (fasting and 2-h postload) andHbA1c
levels and the disorder.
RESEARCH DESIGN AND
METHODSdThe current study is per-
formed using the follow-up data of the
Cooperative Health Research in the Region
of Augsburg (KORA) S4 Survey (1999–
2001): the KORA F4 Survey (2006–2008)
(2). Of the 1,209 participants, 923 par-
ticipants subsequently completed an oral
glucose tolerance test (OGTT) (according
to World Health Organization criteria) (3),
and self-reported diabetes was validated for
177 participants. Clinical DSPN was de-
fined as bilaterally impaired foot-vibration
perception (tuning fork) and/or bilaterally
impaired foot-pressure sensation (10-g
monofilament). Details on a validation
study of the DSPN definition are provided
in the Supplementary Data online.
Age- and sex-adjusted differences in
characteristics were evaluated for the
different categories of glucose tolerance
using ANOVA. Multivariate logistic re-
gression models were fitted to study asso-
ciations between diabetes, prediabetes
(combined impaired fasting glucose
[IFG] and impaired glucose tolerance
[IGT], isolated IFG [i-IFG], and isolated
IGT [i-IGT]), and the presence of clinical
DSPN. In addition, relationships between
glucose concentrations, HbA1c, and clin-
ical DSPN were studied. Analyses were
performed with STATA (version 11;
StataCorp, College Station, TX).
RESULTSdThe results are based on
1,100 participants with complete informa-
tion on glucose tolerance status, clinical
DSPN, and other covariables. The study
population included 577 subjects with
normal glucose tolerance (NGT), 55 with
i-IFG, 183with i-IGT, 46with IFG-IGT, 62
with undiagnosed diabetes, and 177 with
known diabetes. Participants with known
and undiagnosed diabetes were physically
less active and had a larger waist circum-
ference, a higher prevalence of hyperten-
sion, and prior cardiovascular events
compared with subjects with NGT.
The prevalence of clinical DSPN was
similar among participants with IFG-IGT
(23.9% [95% CI 12.6–38.8]) and those
with known diabetes (22.0 [16.2–28.9]).
Prevalence in subjects with NGT, i-IFG,
i-IGT, and undiagnosed diabetes was 11.1
(8.6–13.9), 5.5 (1.1–15.1), 14.8 (10.0–
20.7), and 16.1 (8.0–27.7), respectively.
Subjects with clinical DSPN were slightly
older, taller, and physically less active
than subjects without DSPN and had a
larger waist circumference and higher
HbA1c levels.
The total prediabetic group did not
show statistically significantly increased
odds of having clinical DSPN compared
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with the NGT group (Table 1). When the
subgroups were examined separately, a
positive association was observed be-
tween IFG-IGT and clinical DSPN (odds
ratio [OR] 2.82 [95% CI 1.29–6.10]).
Compared with NGT subjects, partici-
pants with diabetes (undiagnosed and di-
agnosed) had increased odds of having
clinical DSPN (1.54 [1.01–2.42]). This el-
evated risk was largely attributable to sub-
jects with known diabetes, given that no
associationwas observed for subjects with
undiagnosed diabetes.
A J-shaped relationship was observed
between quartiles of 2-h postload blood
glucose and the presence of clinical DSPN
(Table 1). There was no relationship be-
tween quartiles of fasting blood glucose
and quartiles of HbA1c levels and the dis-
order. In addition, there was no association
between (components of) metabolic syn-
drome and clinicalDSPN (data not shown).
CONCLUSIONSdThe present popu-
lation-based study showed a similar prev-
alence of clinical DSPN in participants with
IFG-IGT and those with known diabetes.
Among the prediabetic subgroups, only
IFG-IGT was positively associated with
having clinical DSPN, while the total pre-
diabetic groupwas not related to having the
disorder. A J-shaped relationship was ob-
served between quartiles of 2-h postload
glucose and the presence of clinical DSPN.
No associations were seen with fasting glu-
cose and HbA1c levels.
In the current literature, the preva-
lence of DSPN varies between 18 and 42%
for populations with known diabetes (4,5)
and between 4 and 19% for populations
with prediabetes (6–10). The prevalence
found in the current study for both diabetic
groups is in concordance with the litera-
ture. Published prevalences for subjects
with prediabetes, or IGT only, ranged
from 5 to 16% (4,7,11,12). The proportion
of clinical DSPN that we found in subjects
with IGT is in line with these observations.
Occurrence of DSPN in IFG was reported
less frequently (11–13) yet was within a
range of 5.7–11.3% comparable with our
study estimate. Prevalence of clinical DSPN
in individuals suffering from IFG-IGT has
not been published before. Our findings
indicate that participants with IFG-IGT
were similar to participants with diabetes
regarding characteristics and frequency of
clinical DSPN. Consequently, subjects with
IFG-IGT represent a high-risk group for
DSPN.
Considering glycemia, 2-h postload
glucose concentrations appeared more im-
portant for DSPN risk than fasting glucose
levels. Risk of clinical DSPN was increased
at postload glucose concentrations that
were still within the normal range of the
glycemic metabolism according to the
World Health Organization (3). Previous
studies show similar curvilinear relation-
ships between 2-h postload glucose con-
centrations and risk of (cardiovascular)
mortality (14,15). Altogether, these results
suggest an important role of postprandial
glucose levels, including those below the
diagnostic threshold, in the development
of diabetes complications.
The current study has some limitations.
Since there is no uniform consensus on a
definition of DSPN for use in epidemiolog-
ical studies, we may have under- or over-
estimated the true prevalence of DSPN.
However, a validation study of our clinical
DSPNdefinition showed excellent diagnos-
tic performance (see Supplementary Data
online). Additional adjustment of our ana-
lyses for other risk factors of DSPN (smoking
anddiseases causingneurologic damage) did
not change the results. Finally, stratified
analyses resulted in some small subgroups.
An important methodological strength
of the current study, as opposed to other
previous population-based studies, is the
use of the OGTT. This enables studying
the entire spectrum of glucose disorders
through identification of subjects with
undiagnosed diabetes and prediabetes.
Another strength of the study is the use
of different neurologic bedside tests,
facilitating a relatively accurate definition
of clinical DSPN.
Replication of the present findings
in large, well-defined, population-based
Table 1dAdjusted ORs* and 95% CIs for clinical DSPN† according to oral glucose
tolerance status and blood concentrations: KORA F4 (2006–2008)
Clinical DSPN
OR 95% CINo Yes
Oral glucose tolerance status
NGT 513 64 1.00 Reference
Prediabetes (total) 243 41 1.22 0.78–1.90
i-IFG 52 3 0.33 0.10–1.13
i-IGT 156 27 1.26 0.76–2.08
IFG-IGT 35 11 2.82 1.29–6.10
Diabetes (total) 190 49 1.54 1.01–2.42
Known diabetes 138 39 1.77 1.10–2.87
Undiagnosed diabetes 52 10 1.22 0.57–2.61
Blood concentrations
Fasting glucose (mg/dL)‡x
Quartile 1 222 31 1.00 0.57–1.76
Quartile 2 195 29 1.00 Reference
Quartile 3 191 27 0.96 0.53–1.71
Quartile 4 200 28 0.82 0.43–1.54
2-h postload glucose (mg/dL)|x
Quartile 1 212 27 1.64 0.84–3.20
Quartile 2 208 16 1.00 Reference
Quartile 3 197 36 2.91 1.51–5.62
Quartile 4 191 36 3.64 1.56–8.48
HbA1c (%){
Quartile 1 281 32 0.74 0.45–1.21
Quartile 2 292 48 1.00 Reference
Quartile 3 156 21 0.82 0.46–1.45
Quartile 4 217 53 1.15 0.70–1.87
*All models were adjusted for age (years), sex, height (cm), waist circumference (cm), diastolic blood
pressure (mmHg), level of physical activity (low/high), and alcohol consumption (low, moderate, high).
†Defined as the presence of an impaired bilateral foot-vibration perception and/or an impaired bilateral foot-
pressure sensation. ‡The quartile borders for fasting glucose levels are quartile 1: 66–91 mg/dL; quartile
2: 92–97 mg/dL; quartile 3: 98–104 mg/dL; and quartile 4: 105–168 mg/dL. xPatients with known diabetes
(n = 177) were excluded because they did not need to undergo an OGTT and, hence, have inadequate fasting
and no postload glucose blood samples. |The quartile borders for 2-h glucose values are quartile 1: 49–99
mg/dL; quartile 2: 100–119 mg/dL; quartile 3: 120–149 mg/dL; and quartile 4: 150–275 mg/dL. {The
quartile borders for HbA1c levels are quartile 1: 4.7–5.4%; quartile 2: 5.5–5.7%; quartile 3: 5.8–5.9%; and
quartile 4: 6.0–12.1%.
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studies may shed light on the developmen-
tal mechanism of DSPN and on identifying
high-risk individuals.
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